TG100801

DRUG2 trials

Sponsors

TargeGen

Conditions

Choroidal NeovascularizationDiabetic RetinopathyMacular Degeneration

Phase 1

A Phase 1 Safety Study of TG100801 Eye Drops in Healthy Volunteers

CompletedNCT00414999

TargeGenDiabetic Retinopathy, Macular Degeneration

Start: 2006-11-30End: 2007-02-28Updated: 2007-07-30

Phase 2

Open-Label, Pilot Study of TG100801 in Patients With Choroidal Neovascularization Due to AMD

TerminatedNCT00509548

TargeGenChoroidal Neovascularization, Macular Degeneration

Start: 2007-07-31End: 2008-03-31Updated: 2010-03-29